Document is current
Any future updates will be listed below
-
Authors
Fieuws, Charlotte https://orcid.org/0000-0002-1567-2075
Van der Meulen, Joni https://orcid.org/0000-0002-1916-2769
Proesmans, Kristiaan https://orcid.org/0000-0002-7787-9397
De Jaeghere, Emiel A.
Loontiens, Siebe https://orcid.org/0000-0002-4602-4580
Van Dorpe, Jo https://orcid.org/0000-0001-8175-2930
Tummers, Philippe
Denys, Hannelore https://orcid.org/0000-0002-8897-9430
Van de Vijver, Koen
Claes, Kathleen B. M. https://orcid.org/0000-0003-0841-7372
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1S73622N)
Fonds Wetenschappelijk Onderzoek (1S73622N)
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 8 March 2024
First Online: 22 March 2024
Competing interests
: H.D. reports consulting fees (advisory role) paid to her institution by Pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly, Novartis, Amgen, GSK, MSD, Seagen, Gilead and other fees paid to her institution (travel, accommodations, expenses) by Pfizer, Roche, PharmaMar, Teva, AstraZeneca, MSD, GSK, Gilead and an institutional research grant by Gilead.
